Table 3

Socio-demographic and clinical characteristics by treatment stage and renal function status among patients treated for T2DM in 2010
Patients with normal renal function Patients with declining renal function
Mono-therapy Double therapy Triple therapy Insulin therapy Non diabetic patients Mono-therapy Double therapy Triple therapy Insulin therapy
Number of patients 4,353 2,503 728 1,032 27,389 411 267 78 267
Female (N,%) 48.0% 46.1% 43.4% 53.7% 47.6% 45.3% 44.9% 35.9% 47.2%
Age (mean, sd) (1) 67.7 (11.5) 66.3 (11.1) 64.0 (10.1) 67.4 (11.9) 66.9(11.4) 69.6 (11.0) 67.3 (11.6) 66.0 (10.3) 71.4 (10.0)
Out of metropolitan France 4.5% 5.3% 5.9% 8.6% - 6.6% 9.4% 7.7% 10.1%
CMU* beneficiary 2.5% 3.4% 4.3% 3.3% 3.3% 4.9% 6.0% 3.9% 3.0%
Reimbursement rate for antidiabetics (mean, sd) 90.9 (15.6) 95.7 (12.0) 97.2 (10.3) 98.1 (8.1) - - - - -
Antihypertensive 79.0% 79.0% 81.2% 86,0% 47.8% 88.3% 85.8% 93.6% 96.3%
Antithrombotic agents 41.3% 41.9% 40.3% 60.3% 22.7% 49.4% 44.9% 32.1% 74.5%
Hypolipidemic drugs 62.8% 65.0% 72.1% 69.0% 33.0% 67.4% 67.8% 71.8% 79.8%
ALD*-5: Cardiac Insufficiency 2.8% 1.8% 1.7% 2.4% 1.7% 4.4% 2.3% 2.6% 1.9%
ALD-8: Diabetes 32.9% 50.1% 62.9% 75.6% - 41.6% 56.6% 73.1% 77.9%
ALD-12: Hypertension 10.9% 9.8% 9.9% 10.2% 3.0% 13.1% 18.0% 14.1% 12.0%
ALD-13: Myocardial infarction 5.7% 5.1% 3.7% 5.6% 3.7% 7.5% 3.8% 1.3% 7.1%
ALD-23: Psychosis 4.0% 4.0% 5.5% 6.5% 3.5% 2.9% 3.8% 2.6% 4.5%
ALD-30: Malignant cancer 5.8% 5.0% 3.2% 3.5% 5.5% 7.1% 6.7% 2.6% 5.6%

*CMU = Couverture maladie universelle (Universal health care coverage).

Guelfucci et al.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15

Open Data